CC BY-NC-ND 4.0 · J Lab Physicians 2014; 6(01): 001-006
DOI: 10.4103/0974-2727.129082
How do I do it?

Detection of AmpC β Lactamases in Gram-negative Bacteria

Gunjan Gupta
Department of Laboratory Medicine, Jai Prakash Narain Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
,
Vibhor Tak
Department of Laboratory Medicine, Jai Prakash Narain Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
,
Purva Mathur
Department of Laboratory Medicine, Jai Prakash Narain Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
Source of Support: We acknowledge the financial support of ICMR for the performance of this study.

ABSTRACT

AmpC β-lactamases are clinically important cephalosporinases encoded on the chromosomes of many Enterobacteriaceae and a few other organisms, where they mediate resistance to cephalothin, cefazolin, cefoxitin, most penicillins, and β-lactamase inhibitor/β-lactam combinations. The increase in antibiotic resistance among Gram-negative bacteria is a notable example of how bacteria can procure, maintain and express new genetic information that can confer resistance to one or several antibiotics. Detection of organisms producing these enzymes can be difficult, because their presence does not always produce a resistant phenotype on conventional disc diffusion or automated susceptibility testing methods. These enzymes are often associated with potentially fatal laboratory reports of false susceptibility to β-lactams phenotypically. With the world-wide increase in the occurrence, types and rate of dissemination of these enzymes, their early detection is critical. AmpC β-lactamases show tremendous variation in geographic distribution. Thus, their accurate detection and characterization are important from epidemiological, clinical, laboratory, and infection control point of view. This document describes the methods for detection for AmpC β-lactamases, which can be adopted by routine diagnostic laboratories.



Publication History

Article published online:
19 April 2020

© 2014.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 
  • REFERENCES

  • 1 Kaurthe J. Increasing antimicrobial resistance and narrowing therapeutics in typhoidal salmonellae. J Clin Diagn Res 2013;7:576-9.
  • 2 Laxminarayan R, Klugman KP. Communicating trends in resistance using a drug resistance index. BMJ Open 2011;1:e000135.
  • 3 Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201.
  • 4 Hanson ND. AmpC beta-lactamases: What do we need to know for the future? J Antimicrob Chemother 2003;52:2-4.
  • 5 Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002;40:2153-62.
  • 6 Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino-and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1990;34:2200-9.
  • 7 Mirelis B, Rivera A, Miró E, Mesa RJ, Navarro F, Coll P. A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli. Enferm Infecc Microbiol Clin 2006;24:370-2.
  • 8 Handa D, Pandey A, Asthana AK, Rawat A, Handa S, Thakuria B. Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli. Indian J Pathol Microbiol 2013;56:135-8.
  • 9 Performance Standards for Antimicrobial Susceptibility Testing, 20th Informational Supplement. M100-S 21. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
  • 10 Thomson KS. Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues. J Clin Microbiol 2010;48:1019-25